Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kälebo P, Panfilov S, Eskilson C, Andersson M, Freij A; EXPRESS Study Group. Eriksson BI, et al. Among authors: panfilov s. J Thromb Haemost. 2003 Dec;1(12):2490-6. doi: 10.1111/j.1538-7836.2003.00494.x. J Thromb Haemost. 2003. PMID: 14675083 Free article. Clinical Trial.
The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial.
Kitas GD, Abreu G, Jedrychowicz-Rosiak K, Miller JL, Nakov R, Panfilov S, Vencovsky J, Wang M, Weinblatt ME, White WB. Kitas GD, et al. Among authors: panfilov s. J Am Soc Hypertens. 2014 Nov;8(11):780-90. doi: 10.1016/j.jash.2014.08.013. Epub 2014 Sep 4. J Am Soc Hypertens. 2014. PMID: 25455003 Clinical Trial.
Postoperative Melagatran/Ximelagatran for the Prevention of Venous Thromboembolism following Major Elective Orthopaedic Surgery : Effects of Timing of First Dose and Risk Factors for Thromboembolism and Bleeding Complications on Efficacy and Safety.
Dahl OE, Eriksson BI, Agnelli G, Cohen AT, Mouret P, Rosencher N, Panfilov S, Bylock A, Andersson M. Dahl OE, et al. Among authors: panfilov s. Clin Drug Investig. 2005;25(1):65-77. doi: 10.2165/00044011-200525010-00006. Clin Drug Investig. 2005. PMID: 17523747
In Silico and In Vitro Mapping of Receptor-Type Protein Tyrosine Phosphatase Receptor Type D in Health and Disease: Implications for Asprosin Signalling in Endometrial Cancer and Neuroblastoma.
Orton S, Karkia R, Mustafov D, Gharanei S, Braoudaki M, Filipe A, Panfilov S, Saravi S, Khan N, Kyrou I, Karteris E, Chatterjee J, Randeva HS. Orton S, et al. Among authors: panfilov s. Cancers (Basel). 2024 Jan 30;16(3):582. doi: 10.3390/cancers16030582. Cancers (Basel). 2024. PMID: 38339334 Free PMC article.
Transcriptional Landscape of 3D vs. 2D Ovarian Cancer Cell Models.
Kerslake R, Belay B, Panfilov S, Hall M, Kyrou I, Randeva HS, Hyttinen J, Karteris E, Sisu C. Kerslake R, et al. Among authors: panfilov s. Cancers (Basel). 2023 Jun 26;15(13):3350. doi: 10.3390/cancers15133350. Cancers (Basel). 2023. PMID: 37444459 Free PMC article.
28 results